BIOMAT Database Logo BIOMAT Database Logo

Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. 2014

Anna-Maria Monforte, and Stefania Ferro, and Laura De Luca, and Giuseppa Lo Surdo, and Francesca Morreale, and Christophe Pannecouque, and Jan Balzarini, and Alba Chimirri
Dipartimento di Scienze del Farmaco e Prodotti per la Salute, Università di Messina, Viale Annunziata, I-98168 Messina, Italy. Electronic address: ammonforte@unime.it.

A series of novel N1-aryl-2-arylthioacetamido-benzimidazoles were synthesized and evaluated as inhibitors of human immunodeficiency virus type-1 (HIV-1). Some of them proved to be effective in inhibiting HIV-1 replication at submicromolar and nanomolar concentration acting as HIV-1 non-nucleoside RT inhibitors (NNRTIs), with low cytotoxicity. The preliminary structure-activity relationship (SAR) of these new derivatives was discussed and rationalized by docking studies.

UI MeSH Term Description Entries
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

Anna-Maria Monforte, and Stefania Ferro, and Laura De Luca, and Giuseppa Lo Surdo, and Francesca Morreale, and Christophe Pannecouque, and Jan Balzarini, and Alba Chimirri
Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.
February 2019, ACS medicinal chemistry letters,
Anna-Maria Monforte, and Stefania Ferro, and Laura De Luca, and Giuseppa Lo Surdo, and Francesca Morreale, and Christophe Pannecouque, and Jan Balzarini, and Alba Chimirri
Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.
December 1997, Journal of medicinal chemistry,
Anna-Maria Monforte, and Stefania Ferro, and Laura De Luca, and Giuseppa Lo Surdo, and Francesca Morreale, and Christophe Pannecouque, and Jan Balzarini, and Alba Chimirri
C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors.
December 2008, Bioorganic & medicinal chemistry,
Anna-Maria Monforte, and Stefania Ferro, and Laura De Luca, and Giuseppa Lo Surdo, and Francesca Morreale, and Christophe Pannecouque, and Jan Balzarini, and Alba Chimirri
Design, synthesis, and SAR of naphthyl-substituted Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
September 2009, ChemMedChem,
Anna-Maria Monforte, and Stefania Ferro, and Laura De Luca, and Giuseppa Lo Surdo, and Francesca Morreale, and Christophe Pannecouque, and Jan Balzarini, and Alba Chimirri
Synthesis and biological evaluation of aryl-phospho-indole as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
January 2011, Journal of medicinal chemistry,
Anna-Maria Monforte, and Stefania Ferro, and Laura De Luca, and Giuseppa Lo Surdo, and Francesca Morreale, and Christophe Pannecouque, and Jan Balzarini, and Alba Chimirri
Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
April 2006, Bioorganic & medicinal chemistry letters,
Anna-Maria Monforte, and Stefania Ferro, and Laura De Luca, and Giuseppa Lo Surdo, and Francesca Morreale, and Christophe Pannecouque, and Jan Balzarini, and Alba Chimirri
Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
August 2006, Bioorganic & medicinal chemistry letters,
Anna-Maria Monforte, and Stefania Ferro, and Laura De Luca, and Giuseppa Lo Surdo, and Francesca Morreale, and Christophe Pannecouque, and Jan Balzarini, and Alba Chimirri
Synthesis, biological evaluation and molecular modeling studies of N-aryl-2-arylthioacetamides as non-nucleoside HIV-1 reverse transcriptase inhibitors.
October 2010, Chemical biology & drug design,
Anna-Maria Monforte, and Stefania Ferro, and Laura De Luca, and Giuseppa Lo Surdo, and Francesca Morreale, and Christophe Pannecouque, and Jan Balzarini, and Alba Chimirri
Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
June 2014, Bioorganic & medicinal chemistry,
Anna-Maria Monforte, and Stefania Ferro, and Laura De Luca, and Giuseppa Lo Surdo, and Francesca Morreale, and Christophe Pannecouque, and Jan Balzarini, and Alba Chimirri
[Design, synthesis and biologic evaluation of diarylbenzimidazole derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors].
November 2009, Yao xue xue bao = Acta pharmaceutica Sinica,
Copied contents to your clipboard!